N
NantOmics
Cloud-based molecular profiling tools that help guide cancer patients
About NantOmics
NantOmics is a biotechnology company that provides molecular diagnostic products for personalized cancer treatment. The company is a subsidiary of the NantWorks ecosystem of companies.
NantOmics's services are centered around detecting genomic and proteomic alterations in tumors, which helps in creating personalized treatment plans for cancer patients. The company employs an integrated panomic approach, which involves a comprehensive analysis of a patient's biological data. This approach is used to inform treatment decisions and improve patient outcomes.
The company has developed a cloud-based molecular profiling tool called OncoPlexDx, a targeted proteomic panel that provides information on protein biomarkers. This tool assists in guiding cancer patients toward more effective treatments based on their specific molecular profiles.
NantOmics operates in the cancer diagnostics and personalized medicine market. Its primary clients are oncologists and cancer patients who are seeking more effective and personalized treatment options. The business model is based on providing advanced molecular diagnostic testing services and products.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Culver City, United States
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 60.7/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biomarkers, Medical Data, Tech for Biotech and Pharma, Techbio, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 3 companies, latest Apr 2017
- Capital deployed
- $750K
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Sep 2015 | $150M | $600M | NantHealth | ↗ |
Growth signals
Latest recorded traffic for NantOmics is 3.8K monthly website visits, up 357.8% over the last three months. NantOmics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
GenosSan Francisco, United StatesGenos introduces a revolutionary approach for bettering human health
→
OncoPlexDxRockville, United StatesClia-certified cancer diagnostics laboratory in rockville
→
Translational Research ManagementLos Angeles, United StatesManagement services organization
$3Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
NantHealth
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NantOmics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NantOmics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.